[an error occurred while processing this directive] [an error occurred while processing this directive] [an error occurred while processing this directive]


Cosmos Biomedical's Range of Products and Reagents for Bacteriology

FastPlaqueTB and FastPlaque-Response Diagnostic Assays

Bacteriology Menu, Microbiology Menu

An innovative breakthrough for the detection of Tuberculosis

The new FastPlaqueTB system, developed by BIOTEC Laboratories Ltd and FIND (Foundation for Innovative New Diagnostics) and manufactured by BIOTEC Laboratories Ltd, is a novel application of phage amplifcation technology which allows the rapid detection of TB within 24 hours of sample preparation.

This technology has been further applied to produce the  FastPlaque-Response assay for drug resistance which provides results within 48 hours (see below)





Product Information




50 tests

see details



25 tests

see details 

NOA Antimicrobial Supplement


5 vials (sufficient for one FastPlaque-Response)

see details


Summary of Assay Principle (View schematic flow diagram of FastPlaqueTBDiagnostic Assay)

The benefits of FastPlaqueTB


The FastPlaque-Response assay allows the early detection of rifampicin resistance. This assay allows rapid screening of various patient populations, for example those who have failed or defaulted from the first-line treatment who are at an increased risk of multi-drug resistant tuberculosis (MDR-TB) and those who are not responding to therapy, despite good compliance.

 Summary of Assay Principle (View schematic flow diagram of FastPlaque-ResponseDiagnostic Assay)

  • Process smear positive sputum speciment. Incubate a sample with and without rifampicin overnight at 37oC
  • Add phage to processed specimen. Phage infection occurs
  • Add virucide to destroy extra-cellular phage. TB bacilli and replicating phage within cells are unaffeted
  • Neutralise virucide. Add Sensor cells for amplification of released phage
  • Incorporate reaction mixture into agar in Petri dish and incubater overnight at 37oC. Viable TB bacilli in the original specimen are reflected as clear zones (plaques) in a lawn of Sensor cell growth. Rifampicin resistant TB strains survive drug treatment and product plaques, whilst susceptible strains do not (see below)



FastPlaqueTB and FastPlaque-Response are manufactured by BIOTEC Laboratories Ltd. Please visit their website via this link www.biotec.com

Press Release: FIND and BIOTEC Announce Development of a New Test for Rapid Diagnosis of Multi-Drug Resistant TB


Back to Top

Contact Us

[an error occurred while processing this directive]